Henipavirus Infections

Infections with viruses of the genus HENIPAVIRUS, family PARAMYXOVIRIDAE.

Also Known As:

Hendra Virus Infections; NiV Infection; Nipah Virus Encephalitis; Nipah Virus Infection; Encephalitis, Nipah Virus; Hendra Virus Infection; Henipavirus Infection; Infection, Hendra Virus; Infection, Henipavirus; Infection, NiV; Infection, Nipah Virus; NiV Infections; Virus Encephalitis, Nipah; Virus Infection, Hendra; Virus Infection, Nipah; Virus Infections, Hendra

Networked: 135 relevant articles (12 outcomes, 19 trials/studies)

Relationship Network

Disease Context: Research Results

Infections: 526564
- Virus Diseases: 41777
  - RNA Virus Infections: 303
    - Mononegavirales Infections: 1
      - Paramyxoviridae Infections: 1478
        Henipavirus Infections: 135

Related Diseases

1.	Virus Diseases (Viral Diseases)
2.	Infections
3.	Henipavirus Infections
4.	Inflammation (Inflammations)
5.	COVID-19

Experts

1.	Broder, Christopher C: 17 articles (11/2020 - 06/2005)
2.	Wang, Lin-Fa: 17 articles (01/2018 - 06/2005)
3.	Middleton, Deborah: 9 articles (01/2017 - 12/2006)
4.	Bossart, Katharine N: 9 articles (06/2014 - 06/2005)
5.	Lo, Michael K: 8 articles (11/2020 - 01/2010)
6.	Lee, Benhur: 8 articles (01/2018 - 07/2005)
7.	Mungall, Bruce A: 8 articles (08/2010 - 06/2005)
8.	Crameri, Gary: 8 articles (11/2009 - 06/2005)
9.	Feldmann, Heinz: 7 articles (01/2021 - 10/2010)
10.	Geisbert, Thomas W: 7 articles (11/2020 - 10/2010)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Henipavirus Infections:

1.	VaccinesIBA 11/02/2023 - "These results indicated that vaccines provided complete protection against representative strains of NiV infection and had the potential to be developed as a broad-spectrum vaccine for human use." 01/01/2016 - "A swine vaccine able to prevent shedding of infectious virus is of veterinary and human health importance, and correlates of protection against henipavirus infection in swine need to be better understood. " 11/06/2013 - "However, an international collaborative research has resulted in the identification of a potential equine Hendra vaccine capable of providing antibody protection against Hendra virus infections. " 01/01/2017 - "These studies prove the feasibility of a virus-like particle-based vaccine for protection against Nipah virus infection." 02/01/2013 - "Protection against henipavirus infection by use of recombinant adeno-associated virus-vector vaccines."
2.	Neutralizing AntibodiesIBA 01/01/2019 - "Although the minimal levels for protection of neutralizing antibody in passive immunization were slightly higher than those in active immunization, neutralizing antibody played a key role in protection against Nipah virus infection. " 01/01/2023 - "Neutralizing antibody to NiV has been proposed as the principal mediator of protection against future NiV infection. " 01/01/2023 - "AGMs vaccinated at 7 or 14 days before challenge had either undetectable or low neutralizing antibody titers pre-challenge but had a rapid rise in titers after challenge that abrogated the NiV infection. "
3.	Glycoproteins (Glycoprotein)IBA 01/01/2023 - "A hallmark of henipavirus infection is the induction of cell-cell fusion (syncytia), caused by the expression of the attachment (G) and fusion (F) glycoproteins on the surface of infected cells. " 10/01/2019 - "An antibody against the F glycoprotein inhibits Nipah and Hendra virus infections." 01/01/2017 - "NiV infection is initiated after binding of the viral G glycoprotein to the host cell receptor. " 11/08/2010 - "Nipah virus infection and glycoprotein targeting in endothelial cells." 12/24/2008 - "Our findings clearly show that EB2 signaling does not account for the striking negative impact of elevated receptor expression on NiV infection, but rather that the ratio between the NiV envelope glycoproteins and surface receptors critically influence cell-to-cell fusion and virus entry."
4.	Monoclonal AntibodiesIBA 06/25/2014 - "Therapeutic treatment of Nipah virus infection in nonhuman primates with a neutralizing human monoclonal antibody." 10/01/2009 - "A neutralizing human monoclonal antibody protects against lethal disease in a new ferret model of acute nipah virus infection." 10/01/2004 - "These Nipah virus-specific monoclonal antibodies may therefore be useful for immunohistological diagnosis of Nipah virus infection and for further research on Nipah virus pathogenesis." 08/01/2004 - "Monoclonal antibody-based immunohistochemical diagnosis of Malaysian Nipah virus infection in pigs." 02/01/2006 - "In the present study, we have developed monoclonal antibodies (MAbs) to both glycoproteins and assessed their ability to protect animals against lethal NiV infection. "
5.	Subunit VaccinesIBA 12/01/2006 - "These results indicate that the cat provides a consistent model for acute NiV infection and associated pathogenesis and an effective subunit vaccine strategy appears achievable." 01/01/2022 - "The aforementioned results indicated that the subunit vaccine could be used as a promising candidate vaccine for preventing Nipah virus infection." 12/01/2006 - "Here we have assessed the cat as a model of experimental NiV infection and use it in the evaluation of a subunit vaccine comprised of soluble G glycoprotein (sG). " 12/01/2006 - "Feline model of acute nipah virus infection and protection with a soluble glycoprotein-based subunit vaccine." 08/08/2012 - "We show that vaccination of AGMs with a recombinant subunit vaccine based on the henipavirus attachment G glycoprotein affords complete protection against subsequent NiV infection with no evidence of clinical disease, virus replication, or pathology observed in any challenged subjects. "
6.	Peptides (Polypeptides)IBA 07/18/2005 - "The improved synthesis and solubility characteristics of the second generation HR-2 peptides will facilitate peptide synthesis for pre-clinical trial application in an animal model of Henipavirus infection. " 07/18/2005 - "Nipah virus and Hendra virus infection in vitro can be potently blocked by specific HR-2 peptides. " 10/28/2010 - "Furthermore, we show that cholesterol tagging renders these peptides active in vivo: the cholesterol-tagged peptides cross the blood brain barrier, and effectively prevent and treat in an established animal model what would otherwise be fatal Nipah virus encephalitis. " 10/01/2007 - "We previously reported that a human parainfluenza virus 3 (HPIV3) F peptide effectively inhibits infection mediated by the HeV glycoproteins in pseudotyped-HeV entry assays more effectively than the comparable HeV-derived peptide, and we now show that this peptide inhibits live-HeV and -NiV infection. "
7.	remdesivirIBA 01/01/2023 - "Thus, early administration seems critical for effective remdesivir treatment during Nipah virus infection." 01/01/2023 - "Late remdesivir treatment initiation partially protects African green monkeys from lethal Nipah virus infection." 01/01/2023 - "Remdesivir is a nucleotide prodrug with preclinical efficacy against lethal Nipah virus infection in African green monkeys when administered 1 day post inoculation (dpi) (Lo et al., 2019). " 01/01/2019 - "In contrast to control animals, which all succumbed to the infection, all remsdesivir-treated animals survived the lethal challenge, indicating that remdesivir represents a promising antiviral treatment for Nipah virus infection."
8.	Attenuated VaccinesIBA 01/01/2023 - "Advancements in vaccine research, including live-attenuated vaccines, virus-like particles, and mRNA-based vaccines, hold promise for preventing NiV infections. "
9.	Messenger RNA (mRNA)IBA 01/01/2023 - "Advancements in vaccine research, including live-attenuated vaccines, virus-like particles, and mRNA-based vaccines, hold promise for preventing NiV infections. "
10.	ProTidesIBA 01/01/2023 - "Remdesivir is a nucleotide prodrug with preclinical efficacy against lethal Nipah virus infection in African green monkeys when administered 1 day post inoculation (dpi) (Lo et al., 2019). "

Therapies and Procedures

1.	Therapeutics 06/25/2014 - "Studies in small-animal models of NiV infection suggest that antibody therapy may be a promising treatment. " 01/01/2020 - "Currently, no therapeutics are approved for use in humans against NiV infection. " 04/01/2007 - "We discuss how the identification of the henipahvirus receptor sheds light on the pathobiology of NiV infection, and how it will spur the rational development of effective therapeutics. " 02/01/2006 - "Antibody prophylaxis and therapy against Nipah virus infection in hamsters." 07/21/2005 - "Identification of the receptor for this virus will shed light on the pathobiology of NiV infection, and spur the rational development of effective therapeutics. "
2.	Immunotherapy 02/01/2006 - "Our studies suggest that immunotherapy could be used for people who are exposed to NiV infections."
3.	Personal Protective Equipment 06/01/2007 - "No evidence of recent Nipah virus infection was detected despite substantial exposures and minimal use of personal protective equipment." 04/01/2006 - "This outbreak highlights the importance and urgency of establishing a strong surveillance system supported by a network of state-of-the-art laboratories equipped to handle and diagnose new pathogens and including patient isolation techniques, use of personal protective equipment, barrier nursing and safe disposal of potentially infected material in the prevention and control measures for Nipah/Hendra virus infection."
4.	Patient Isolation 04/01/2006 - "This outbreak highlights the importance and urgency of establishing a strong surveillance system supported by a network of state-of-the-art laboratories equipped to handle and diagnose new pathogens and including patient isolation techniques, use of personal protective equipment, barrier nursing and safe disposal of potentially infected material in the prevention and control measures for Nipah/Hendra virus infection."